The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Results from a Phase I study of rapcabtagene autoleucel (YTB323), a novel CAR-T therapy in DLBCL
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the key results of a Phase I study evaluating the use of rapcabtagene autoleucel (YTB323), a novel autologous CAR-T therapy, for the treatment of diffuse large B-cell lymphoma (DLBCL). Dr Dickinson first discusses the manufacturing process used in the development of this product, and then highlights the promising results observed in patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Funding, research & consulting: Novartis, Roche, Kite/Gilead, BMS, Takeda
